AbbVie Inc (ABBV)vsSophia Genetics SA (SOPH)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
SOPH
Sophia Genetics SA
$7.87
+3.42%
HEALTHCARE · Cap: $688.68M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 74622% more annual revenue ($64.39B vs $86.17M). ABBV leads profitability with a 9.8% profit margin vs -93.9%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
SOPH
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for SOPH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 27.2% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 8.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : SOPH
The strongest argument for SOPH centers on Revenue Growth. Revenue growth of 27.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : SOPH
The primary concerns for SOPH are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while SOPH is a growth play — different risk/reward profiles.
SOPH carries more volatility with a beta of 0.98 — expect wider price swings.
SOPH is growing revenue faster at 27.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 27/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Sophia Genetics SA
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Sophia Genetics SA (SOPH) stands at the forefront of data-driven medicine, delivering advanced genomic and clinical data analytics that significantly enhance patient outcomes. Utilizing cutting-edge machine learning technologies, the company provides an integrated platform designed to help healthcare providers navigate complex genomic data, facilitating personalized treatment strategies in oncology, rare diseases, and hereditary conditions. With a robust global footprint and strategic partnerships with leading healthcare organizations, Sophia Genetics is well-positioned to transform the precision medicine landscape and solidify its role as a key player in the genomics industry.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?